Compositions and methods using β-hydroxy-β-methylbutyrate (HMB) and probiotics

Combining HMB with probiotics, especially Bacillus coagulans, addresses the limitations of HMB alone by enhancing absorption and reducing inflammatory markers, thus maintaining muscle integrity during intense training.

JP7583523B2Active Publication Date: 2024-11-14METABOLIC TECHNOLOGIES INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2019521016
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-10-21
Filing Date
2017-10-20
Publication Date
2024-11-14
Estimated Expiration
2037-10-20

AI Technical Summary

Technical Problem

Existing supplements fail to effectively attenuate inflammatory cytokine markers and maintain muscle integrity during intense training, with HMB alone showing limited absorption and efficacy.

Method used

Combining HMB with probiotics, particularly Bacillus coagulans, enhances absorption and circulation of HMB, leading to synergistic effects in reducing inflammatory cytokine markers and maintaining muscle integrity.

Benefits of technology

The combination of HMB and probiotics significantly attenuates inflammatory cytokine markers and improves muscle integrity during intense training, outperforming HMB alone by increasing circulating HMB levels and maintaining muscle health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583523000003
    Figure 0007583523000003
  • Figure 0007583523000004
    Figure 0007583523000004
  • Figure 0007583523000001
    Figure 0007583523000001
Patent Text Reader

Abstract

The present invention provides a composition comprising HMB and at least one probiotic. A method for administering HMB and at least one probiotic to an animal is also described. The HMB and probiotic are administered to attenuate inflammatory cytokine markers and / or maintain muscle integrity. [Selection diagram] None
Need to check novelty before this filing date? Find Prior Art

Description

Related Applications

[0001] 2. Background of the Invention This application claims priority to U.S. Provisional Patent Application No. 62 / 411,200, filed October 21, 2016, which is incorporated herein by reference. [Technical field]

[0002] The present invention relates to compositions comprising β-hydroxy-β-methylbutyrate (HMB) and a probiotic, and methods of using the compositions to attenuate inflammatory cytokine markers and / or maintain muscle integrity. [Background technology]

[0003] HMB Alpha-ketoisocaproate (KIC) is the first major active metabolic product of leucine. The minor product of KIC metabolism is β-hydroxy-β-methylbutyrate (HMB). HMB has been found to be useful for a variety of applications. Specifically, in U.S. Patent No. 5,360,613 (Nissen), HMB is described as being useful for lowering blood levels of total cholesterol and low-density lipoprotein cholesterol. In U.S. Patent No. 5,348,979 (Nissen et al.), HMB is described as being useful for promoting nitrogen retention in humans. In U.S. Patent No. 5,028,440 (Nissen) the utility of HMB for increasing lean tissue development in animals is discussed. In U.S. Patent No. 4,992,470 (Nissen), HMB is also described as being effective in enhancing immune response in mammals. U.S. Patent No. 6,031,000 (Nissen et al.) describes the use of HMB and at least one amino acid to treat disease-related weakness.

[0004] The use of HMB to inhibit protein breakdown stems from the observation that leucine has protein-sparing properties. Leucine, an essential amino acid, can either be used in protein synthesis or transaminated to an α-keto acid (α-ketoisocaproate, KIC). In one pathway, KIC can be oxidized to HMB, which accounts for approximately 5% of leucine oxidation. HMB is superior to leucine in enhancing muscle mass and strength. Optimal action of HMB can be achieved at 3.0 grams / day, or 0.038 g / kg body weight / day, when given as the calcium salt of HMB, whereas optimal action of leucine requires more than 30.0 grams / day.

[0005] HMB is believed to have two fates once produced or ingested. The first fate is simple excretion in the urine. After HMB is administered, urinary concentrations increase, resulting in an approximate 20-50% loss of HMB to urine. The other fate involves activation of HMB to HMB-CoA. Once converted to HMB-CoA, further metabolism can either dehydrate HMB-CoA to MC-CoA or convert HMB-CoA directly to HMG-CoA, thereby providing a substrate for intracellular cholesterol synthesis. Numerous studies have shown that HMB can be incorporated into the cholesterol synthesis pathway and become a source for new cell membranes to be used in the regeneration of damaged cell membranes. Human studies have shown that muscle injury after intense exercise, as measured by elevated plasma CPK (creatine phosphokinase), is reduced with initial HMB supplementation within 48 hours. The protective effects of HMB continue for up to three weeks with continued daily use. Numerous studies have shown that an effective dose of HMB is 3.0 grams / day (approximately 38 mg / kg body weight / day) of CaHMB (calcium HMB). HMB has been tested for safety and shown to have no side effects in healthy young or older adults. HMB in combination with L-arginine and L-glutamine has also been shown to be safe when supplemented to AIDS and cancer patients.

[0006] Recently, a new delivery form of HMB, HMB free acid, has been developed.This new delivery form has been shown to be absorbed more quickly than CaHMB and has greater tissue clearance than CaHMB.The new delivery form is described in US Patent Publication No. 20120053240, the entirety of which is incorporated herein by reference.

[0007] HMB has been shown to enhance recovery from high-intensity exercise and attenuate muscle damage associated with it. HMB attenuates the decline in protein synthesis associated with TNF-alpha and reduces TNF-associated protein degradation.

[0008] Studies investigating strenuous physical activity with minimal recovery, such as that encountered by soldiers during prolonged combat operations, have shown that the use of HMB supplementation can mitigate the deleterious effects associated with this physical stress. Significant losses in body weight, strength, and physical fitness have been reported in soldiers during prolonged military operations. These stresses are also associated with significant elevations in inflammatory cytokine markers. Recent field studies have demonstrated that supplementation of soldiers with HMB for three weeks during intense training, including simulated combat, attenuated the inflammatory response and concomitantly maintained muscle integrity, as determined by diffusion tensor imaging. These results were consistent with other studies reporting that short (e.g., 4 days) and long (e.g., 12 weeks) duration HMB supplementation can attenuate cytokine responses to muscle-injuring protocols.

[0009] Probiotics The use of probiotics as dietary supplements has become very popular over the past few years for the prevention and treatment of various diseases. Probiotics are live bacteria that have been suggested to be beneficial in improving digestive health and immune function while reducing inflammation. It is believed that probiotics, such as Bacillus coagulans, can enhance the enzymatic digestion of food in the digestive tract, resulting in more nutrients being absorbed. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] U.S. Patent No. 5,360,613 [Patent Document 2] U.S. Patent No. 5,348,979 [Patent Document 3] U.S. Patent No. 5,028,440 [Patent Document 4] U.S. Patent No. 4,992,470 [Patent Document 5] U.S. Patent No. 6,031,000 [Patent Document 6] U.S. Patent Publication No. 20120053240 Summary of the Invention [Problem to be solved by the invention]

[0011] Surprisingly and unexpectedly, it has been found that the combination of HMB and probiotics attenuates inflammatory cytokine markers and maintains muscle integrity.The reduction of cytokine response to intense training is often used to indicate more favorable recovery from high-intensity training.The combination of HMB and probiotics enhances HMB absorption and increases circulating HMB compared to administration of HMB alone, so such combination is synergistic.This synergistic effect of HMB and probiotics is demonstrated by the improved attenuation of inflammatory cytokine markers and muscle integrity compared to the effect of HMB administered alone. [Means for solving the problem]

[0012] One object of the present invention is to provide a composition for use in maintaining muscle integrity. Another object of the present invention is to provide compositions for use in attenuating inflammatory cytokine markers.

[0013] It is a further object of the present invention to provide a method of administering a composition for use in maintaining muscle integrity. It is an additional object of the present invention to provide methods of administering compositions for use in attenuating inflammatory cytokine markers.

[0014] Another object of the present invention is to provide a method for improving the absorption of HMB by adding a probiotic to a composition containing HMB. It is an additional object of the present invention to provide a method of increasing the time HMB is present in the bloodstream by adding a probiotic to a composition containing HMB.

[0015] These and other objects of the present invention will become apparent to those skilled in the art upon review of the following specification, drawings, and claims. The present invention aims to overcome the difficulties encountered so far. To this end, a composition is provided that includes HMB and a probiotic. The composition is administered to a subject in need thereof. All methods include administering HMB and a probiotic to an animal. Subjects encompassed by the present invention include humans and non-human mammals. The composition is consumed by a subject in need thereof. [Brief description of the drawings]

[0016] [Figure 1] FIG. 1 shows changes in the inflammatory cytokine response to intense military training after 40 days of supplementation. [Diagram 2] Figure 2 shows the changes in DTI measurements after 40 days of supplementation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] Surprisingly and unexpectedly, it has been found that probiotics and HMB have a synergistic relationship.The use of the composition containing HMB and probiotics results in the attenuation of inflammatory cytokine markers and the maintenance of muscle integrity, and these effects are observed at higher doses than when HMB is administered alone.The combination of HMB and probiotics enhances the absorption of HMB, and increases the amount of HMB in circulation compared to when HMB is administered alone, so this combination is synergistic.

[0018] HMB β-Hydroxy-β-methylbutyric acid, or β-hydroxy-isovaleric acid, in its free acid form, (CH 3 ) 2 (OH)CCH 2It can be expressed as COOH. The term "HMB" refers to the compound having the above chemical formula in both its free acid and salt form, and their derivatives. Although any form of HMB can be used in the present invention, preferably, HMB is selected from the group including free acid, salt, ester, and lactone. HMB esters include methyl and ethyl esters. HMB lactones include isovaleryl lactone. HMB salts include sodium salt, potassium salt, chromium salt, calcium salt, magnesium salt, alkali metal salt, and earth metal salt.

[0019] Methods for producing HMB and its derivatives are well known in the art. For example, HMB can be synthesized by oxidation of diacetone alcohol. One suitable procedure is described by Coffman et al., J. Am. Chem. Soc. 80:2882-2887 (1958). As described therein, HMB is synthesized by alkaline sodium hypochlorite oxidation of diacetone alcohol. The product is recovered in the form of free acid, which can be converted to a salt. For example, HMB can be prepared as its calcium salt by a procedure similar to that of Coffman et al. (1958), in which the free acid of HMB is neutralized with calcium hydroxide and recovered by crystallization from aqueous ethanol. The calcium salt of HMB is commercially available from Metabolic Technologies (Ames, Iowa).

[0020] Calcium β-hydroxy-β-methylbutyrate (HMB) supplementation Over 20 years ago, the calcium salt of HMB was developed as a nutritional supplement for humans. Studies have shown that 38 mg of CaHMB per kg of body weight is considered an effective dosage for the average person.

[0021] The molecular mechanisms by which HMB reduces protein breakdown and increases protein synthesis have been reported. An in vitro study by Eley et al. showed that HMB stimulates protein synthesis via mTOR phosphorylation. Other studies have shown that when muscle protein catabolism is stimulated by proteolysis inducing factor (PIF), lipopolysaccharide (LPS), and angiotensin II, HMB reduces protein degradation via attenuation of the induction of the ubiquitin-proteosome protein degradation pathway. Still other studies have demonstrated that HMB also attenuates the activation of caspase-3 and caspase-8 proteases.

[0022] The free acid form of HMB In most cases, HMB utilized in clinical studies and marketed as a strength-building stimulant has been in the form of a calcium salt. Recent advances have made it possible to produce HMB in the form of a free acid for use as a nutritional supplement. Recently, a new free acid form of HMB has been developed that has been shown to be absorbed more rapidly than CaHMB, resulting in more rapid and higher peak serum HMB levels and improved serum clearance to tissues.

[0023] Therefore, the free acid of HMB may be a more effective method of administering HMB than the calcium salt form, especially when administered directly prior to strenuous exercise, although those skilled in the art will recognize that the present invention encompasses HMB in all forms.

[0024] Any form of HMB can be incorporated into a delivery and / or administration form in a manner that results in a typical dosage range of about 0.5 grams of HMB to about 30 grams of HMB.

[0025] Any suitable dose of HMB can be used in the context of the present invention. Methods for calculating suitable doses are well known in the art. The dosage of HMB can be expressed in terms of the molar amount of the corresponding Ca-HMB. The dosage range in which HMB can be administered orally or intravenously is within the range of 0.01-0.2 grams of HMB (Ca-HMB) per kilogram of body weight per 24 hours. For adults, assuming a body weight of about 100-200 pounds (about 45-91 kg), the oral or intravenous dosage of HMB (Ca-HMB base) may be in the range of 0.5-30 grams / subject / 24 hours.

[0026] Probiotics Probiotics, such as Bacillus coagulans (BC30), have many health benefits, such as improving digestive health and immune function, as well as reducing inflammation. In addition, previous studies have suggested that BC30 can enhance protein absorption. Any probiotic is suitable for use in the compositions described herein. It is expected that the appropriate amount of Bacillus coagulans will be understood by those of skill in the art. An exemplary composition of the present invention contains 2×10 5 ~10 10 In another embodiment, the amount of bacteria is about 1 x 10 4 ~Approx. 1×10 12 The probiotic may be in the form of a spore, a vegetative cell, or a combination thereof. Although Bacillus coagulans was used in the experimental examples, the present invention is not limited to this particular Bacillus species. Any species of probiotic bacteria may be used in the compositions and methods of the present invention.

[0027] When the composition is orally administered in edible form, the composition is preferably in the form of dietary supplement, foodstuff or pharmaceutical medium, more preferably in the form of dietary supplement or foodstuff.Any suitable dietary supplement or foodstuff containing the composition can be utilized in the present invention.Those skilled in the art should understand that the composition can include amino acids, proteins, peptides, carbohydrates, fats, sugars, inorganic substances and / or trace elements, regardless of the form (e.g. dietary supplement, foodstuff or pharmaceutical medium).

[0028] To prepare the composition as a dietary supplement or foodstuff, the composition will generally be combined or mixed in such a way that the composition is substantially uniformly dispersed in the dietary supplement or foodstuff. Alternatively, the composition can be dissolved in a liquid, for example in water.

[0029] The dietary supplement composition may be a powder, gel, liquid, or may be flat or encapsulated. Although any suitable pharmaceutical vehicle containing the present composition may be utilized in accordance with the present invention, preferably the present composition is combined with a suitable pharmaceutical carrier such as dextrose or sucrose.

[0030] Furthermore, the pharmaceutical medium composition can be administered intravenously in any suitable manner. For administration via intravenous infusion, the composition is preferably in a water-soluble, non-toxic form. Intravenous administration is particularly suitable for hospitalized patients undergoing intravenous (IV) therapy. For example, the composition can be dissolved in an IV solution (e.g., saline or glucose solution) administered to the patient. The composition can also be added to a nutritional IV solution, which may include amino acids, glucose, peptides, proteins and / or lipids. The amount of the composition administered intravenously may be similar to the levels used in oral administration. Intravenous infusion can be more highly controlled and precise than oral administration.

[0031] Methods for calculating the frequency at which the composition is administered are well known in the art, and any suitable administration frequency (e.g., one 6 g dose / day or two 3 g doses / day) can be used in the present invention for any suitable period of time (e.g., a single dose can be administered over a 5 minute period or an hour period, or alternatively, multiple doses can be administered over an extended period of time).The composition can be administered over an extended period of time, such as weeks, months, or years.

[0032] Any suitable dose of HMB and probiotic can be used in accordance with the present invention. Methods for calculating appropriate doses are well known in the art. It will be understood by those skilled in the art that in order to practice the claimed methods, the HMB and probiotic are not administered in the same composition. In other words, separate capsules, pills, mixtures, etc. of the probiotic and HMB may be administered to a subject in order to practice the claimed methods.

[0033] The term administering or administration includes providing a composition to a mammal, consuming a composition, and combinations thereof. EXAMPLES

[0034] The following examples further illustrate the present invention. It is expected that the compositions of the present invention can be synthesized in various formulations and dosage forms, as generally described and illustrated in the examples herein. Therefore, the more detailed description of the presently preferred embodiments of the methods, formulations and compositions of the present invention described below is not intended to limit the scope of the invention as claimed, but merely represents the presently preferred embodiments of the invention.

[0035] method participants Twenty-six male soldiers from an elite combat unit of the Israel Defense Forces (IDF) volunteered to participate in this double-blind, parallel-design study. After explaining all procedures, risks, and benefits, each participant provided their own informed consent to participate in the study. The Helsinki Committee of the IDF Medical Corp and the Medical Ethics Committee, as well as the Helsinki Committee of the Soroka Medical Center, approved this research study. Participants were not allowed to use any additional dietary supplementation, and furthermore did not consume any androgen or other performance-enhancing drugs. Screening for the use of performance-enhancing drugs and additional supplementation was accomplished via a health questionnaire that was completed during the participants' supplementation. Soldiers from the same unit were randomly assigned to one of two groups: CaHMB with BC30 (CaHMBBC30; n=9; 20.5±0.8y; 1.75±0.09m; 75.4±9.6kg) or CaHMB with placebo (CaHMBPL; n=9; 19.1±3.4y; 1.73±0.05m; 71.4±6.4kg). A third group of participants from the same unit who expressed interest in participating in the study but were not interested in consuming the supplement agreed to serve as a control group (CTL; ​​n=8; 20.4±0.7y; 1.73±0.05m; 68.6±5.3kg).

[0036] Study Protocol All participants followed the same daily protocol throughout the 40-day intervention period. For the first 28 days, soldiers will be stationed at the base. They participated in the same advanced military training assignments, including combat skill development and conditioning, including 90 minutes of intense close-combat (Krav Maga) training five times a week. Physical training encompassed an average of two 5-km runs per week. During weeks 5 and 6, soldiers marched in the field 25-30 km per night over difficult terrain carrying approximately 35 kg of equipment (equivalent to approximately 40% of the participant's body weight). The duration of this march training ranged from 5-8 hours per night. During the last night of training (day 40), soldiers also performed an additional 5 km stretcher carry after the march training. During the last 2 weeks of training, soldiers' sleep duration ranged from 5-8 hours per night. All assessments (blood sampling and magnetic resonance imaging [MRI]) were performed one day before (PRE) and approximately 12 hours after (POST) the last supplement consumption (day 40). All assessments were performed in the same order, both PRE and POST.

[0037] Supplementation Protocol Participants in both CaHMBBC30 and CaHMBPL consumed 1.0 g CaHMB three times per day for a total daily consumption of 3 g. Each serving consisted of four capsules (250 mg CaHMB) and was consumed during breakfast, lunch, and dinner. CaHMB was obtained from Metabolic Technology, Inc. (Ames, IA, USA). Probiotic supplement (Bacillus coagulans GBI-30, 6086) was provided by Ganeden Biotech, Inc. (Mayfield Heights, OH, USA). Each serving contained 2.0 × 10 10 The CaHMBBC30 and CaHMBPL participants were provided with two 20-day supplies of HMB and PL. At the end of each 20-day period, participants were asked to return all used and unused sachets.

[0038] Blood measurements A resting blood sample was obtained prior to each testing session. All blood samples were obtained after a 15-minute equilibration period. These blood samples were obtained from an antecubital arm vein using a 20-gauge disposable needle with a Vacutainer® tube holder (Becton Dickinson, Franklin Lakes, NJ). Blood samples were obtained for each participant at the same time of day during each session after an overnight fast. All blood samples were collected in two Vacutainer® tubes, where one tube was anticoagulant-free and the second tube was K 2 The blood in the first tube was allowed to clot at room temperature for 30 minutes and then centrifuged with the remaining whole blood from the second tube at 3,000×g for 15 minutes. The resulting plasma and serum were placed into separate 1.8 ml microcentrifuge tubes and frozen at −80° C. for later analysis.

[0039] biochemical analysis Serum concentrations of creatine kinase (CK) and lactate dehydrogenase (LDH) were analyzed using commercially available kinetic assays (Sekisui Diagnostics, Charlottetown, PE, Canada; Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's instructions. Plasma concentrations of cytokines and chemokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF), fractalkine (CX3CL1), interferon-gamma (INF-γ), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-α), were analyzed using one of the human cytokine / chemokine panels (EMD Millipore). Plasma HMB concentrations were analyzed via multiplex assay using a BioTek Eon spectrophotometer (BioTek, Winooski, VT, USA) (EMD Millipore, Billerica, MA, USA). In addition, plasma HMB concentrations were analyzed by gas chromatography mass spectrometry. This was performed using methods previously described by Metabolic Technology, Inc. All samples were thawed once and analyzed in duplicate by the same technician using a BioTek Eon spectrophotometer (BioTek, Winooski, VT, USA) for CK and LDH concentrations, and a MagPix (EMD Millipore) for cytokine and chemokine concentrations. The average interassay variation for all assays was less than 10%.

[0040] Magnetic Resonance Imaging (MRI) Changes in muscle integrity of the rectus femoris (RF) and vastus lateralis (VL) were assessed using MRI. Logistical considerations (time factor) determined a priori that the primary focus of the study was to compare the effects of BC30 administered with CaHMB to CaHMB alone, so only CaHMBBC30 and CaHMBPL soldiers were assessed with MRI. Muscle integrity was determined via diffusion tensor imaging (DTI). DTI is a highly sensitive MRI technique for assessing subclinical signs of muscle damage. DTI assessment is based on cell membranes and other structures that constrain water diffusion. Water movement can be assessed by determining the three orthogonal directions of water diffusion, called eigenvectors, and their intensities, called eigenvalues. From the three eigenvalues ​​(λ1, λ2, and λ3), parameters such as the degree of anisotropy (FA) and apparent diffusion coefficient (ADC) can be calculated to assess the characteristics of water diffusion in a voxel. These measurements have been demonstrated to provide information on skeletal muscle integrity.

[0041] MRI data were obtained using a 3.0 Tesla whole-body imaging device (Ingenia, Philips Medical Systems, Best, The Netherlands). During each measurement, participants were positioned supine in the scanner and imaged using a phased array surface coil. A position 20 cm above the patella was chosen as the center of the image and marked using an oil capsule. All scans were axially planned and consisted of 40 sections of 4 mm width, 160 mm apart from the foot to the head, and a field of view of 290 × 280 mm (RL × AP). Triplicate image acquisitions were performed. T1w DIXON was used as an anatomical reference, T2w Turbo spin-echo was used to assess any structural injury to the muscle, and a diffusion tensor imaging (DTI) sequence was used to track muscle fibers. Sequence parameters used were as previously published.

[0042] Fat suppression (SPAIR - spectrally selective adiabatic inversion recovery) was used for T2-TSE and DTI scans. The DTI sequence was a 2D-EPI sequence imaged with two packages. The b-value was 400 sec / mm2 and imaged in 15 unique directions. Muscle fiber tracking analysis was calculated using Philips' FiberTrak software. RF and VL ROIs (regions of interest) were hand-drawn at cross sections 15 and 25. The software then delineated muscle fibers using an algorithm that erased tracks if the FA was less than 0.1, if the change in angle was greater than 27°, or if the fiber length was less than 10 mm. All evaluations were performed by the same investigator.

[0043] statistical analysis Analysis of covariance (ANCOVA) was used to analyze all MRI and blood dependent variables (markers of muscle injury and cytokines). PRE and POST values ​​were used as covariates and dependent variables, respectively. When f-ratios were significant, LSD post-hoc pairwise comparisons were used to explore differences between groups. ANCOVA results were also converted to change from PRE. For all comparisons, an alpha level of p ≤ 0.05 was considered statistically significant. All data are reported as mean ± SD unless otherwise stated. Statistical analysis was performed using SPSS (IBM Statistics for Windows, version 23.0; Armonk, NY: IBM Corporation).

[0044] result Of the 26 soldiers who participated in the trial, 25 completed the intervention. The only participants who withdrew from the study were those injured during training. There were no supplementation-related side effects reported during the study. Based on CaHMB and BC30 consumption (determined by the number of returned capsules and BC-30 sachets), compliance with supplementation was 95.0 ± 3.0% between the two CaHMB groups. Additional measures of study compliance were performed by analyzing plasma HMB concentrations at PRE and POST for participants in both supplement groups. PRE (3.28 ± 0.73 nmol L -1 ) to POST (34.1 ± 43.9 nmol L -1 ) A significant increase in plasma HMB concentration (p=0.010) was recorded.

[0045] Blood Data The circulating concentrations of inflammatory cytokines can be observed in Table 1. In addition, a comparison of the changes from PRE between the groups is shown in Figure 1. A significant interaction was observed for the changes in circulating TNF-α concentrations (F = 6.48, p = 0.006). For CaHMBBC30 and CaHMBPL, plasma TNF-α concentrations at POST were significantly lower than CTL (p = 0.019 and p = 0.002, respectively). However, no differences were recorded between CaHMBBC30 and CaHMBPL (p = 0.290). For the changes in plasma CX3CL1 concentrations, no significant interaction was recorded between the groups either (F = 4.70, p = 0.025). For CaHMBBC30 and CaHMBPL, changes in CX3CL1 concentrations were significantly lower than CTL (p = 0.044 and p = 0.011, respectively). No difference in CX3CL1 concentrations was recorded between CaHMBBC30 and CaHMBPL (P=0.687). A significant interaction was recorded for changes in plasma IL-1β concentrations (F=6.93, p=0.006). IL-1β concentrations were significantly attenuated for both CaHMBBC30 and CaHMBPL compared to CTL (p=0.005 and p=0.004, respectively). No difference was observed between CaHMBBC30 and CaHMBPL (p=0.878). A significant interaction was also found for plasma IL-2 concentrations (F=4.96, p=0.019). Circulating IL-2 concentrations for CaHMBBC30 and CaHMBPL at POST were significantly attenuated compared to CTL (p=0.007 and p=0.029, respectively). No difference was recorded between CaHMBBC30 and CaHMBPL (p=0.584). A significant interaction was also observed for changes in plasma IL-6 concentrations (F=7.99, p=0.005). Plasma IL-6 concentrations were significantly attenuated in CaHMBBC30 and CaHMBPL compared to CTL (p=0.002 and p=0.018, respectively). No difference was recorded in IL-6 responses at POST between CaHMBBC30 and CaHMBPL (p=0.467). A significant interaction was also observed for changes in plasma IL-10 concentrations (F=3.72, p=0.041).A significant difference was found between CaHMBBC30 and CTL (p=0.013). No other significant differences were recorded. No significant interactions were observed for changes in INF-γ (F=1.25, p=0.31), IL-8 (F=1.49, p=0.25) or GM-CSF (F=0.71, p=0.50) concentrations.

[0046] [Table 1]

[0047] CaHMBBC30 = Calcium HMB and Bacillus coagulans; CaHMBPL = Calcium HMB and placebo; CTL = control. All data are reported as mean ± SD. ANCOVA tests were used to evaluate differences between groups.

[0048] Analysis of markers of muscle injury revealed no significant interactions between groups for plasma LDH (F = 0.15, p = 0.86) or CK concentrations (F = 0.17, p = 0.84). In the combined group, PRE (537.7 ± 86.1 IU L -1 ) to POST (567.5±87.4 IU L -1 ) was not recorded. In addition, in the combined group, PRE (225.4 ± 79.8 IU L -1 No changes were recorded in CK concentrations from IM (377.6 ± 230.2 IU·L-1) to POST (377.6 ± 230.2 IU·L-1).

[0049] DTI A comparison of the FA and ADC assessments between CaHMBBC30 and CaHMBPL can be seen in Table 2.

[0050] [Table 2]

[0051] In addition, Figure 2 shows a comparison of changes from PRE between groups. No significant difference in FA was observed between CaHMBBC30 and CaHMBPL in RF (F = 0.315, p = 0.587), but a significant decrease was recorded from PRE to POST when steeply falling between groups. A significant difference in ADC was recorded between groups in RF (F = 7.198, p = 0.023). CaHMBBC30 participants experienced a decrease in ADC, whereas CaHMBPL participants experienced an increase. No significant difference in VL was recorded between groups for either FA (F = 2.95, p = 0.117) or ADC (F = 1.886, p = 0.200).

[0052] The results of this study show that HMB supplementation with and without Bacillus coagulans for 40 days can attenuate inflammatory cytokine markers during highly strenuous military training. The combination appeared to attenuate IL-10 responses compared to controls. In addition, the combination of CaHMB and BC30 provided a significant benefit compared to CaHMB alone in preserving muscle integrity, as shown by a reduction in apparent diffusion coefficient (ADC) for the rectus femoris (RF).

[0053] Plasma HMB in CaHMBPC30, CaHMBPL and CTL was 50.6 ± 15.6 nmol L -1 , 15.6 ± 28.0 nmol L -1 and 3.3 ± 0.9 nmol L -1 The greater HMB concentration observed for CaHMBBC30 indicates that BC30 has enhanced absorption capacity.

[0054] Measurement of muscle integrity was performed by DTI, where DTI is considered a sensitive method to evaluate subclinical signs of muscle damage. DTI measures the diffusion of water molecules and their direction of movement in three-dimensional muscle microstructure. In healthy tissue, structural integrity is a barrier to diffusion. The anisotropy factor (FA) represents the increase in the rate of diffusion into the tissue after trauma, while the apparent diffusion coefficient (ADC) reflects the degree of diffusion in each direction of the muscle by its axial length. A decrease in FA and an increase in ADC represent a breakdown in muscle integrity, i.e., greater diffusion. The significant decrease in FA in both RF and semitendinosus muscles only in the placebo group and the possible increase in ADC of VL in the supplemented group reported by the inventors so far indicate that HMB provided in the form of free acid can enhance muscle integrity during intense military training. However, the data indicate that the addition of BC30 to CaHMB provides a synergistic effect with respect to maintaining muscle integrity, resulting in a greater degree of muscle protection than that provided by CaHMB alone.

[0055] The foregoing description and drawings include exemplary embodiments of the present invention. The foregoing embodiments and methods described herein may be modified based on the ability, experience, and selection of those skilled in the art. The method steps are merely listed in a particular order, but are not to be considered as any limitation on the method steps. The foregoing description and drawings merely explain and illustrate the present invention, and the present invention is not limited thereto, except as so limited by the claims. It is expected that those skilled in the art, having prior knowledge of the present disclosure, may make modifications and variations therein without departing from the scope of the present invention.

[0056] References 1. Gonzalez AM, Fragala MS, Jajtner AR, et al. Effects of beta-hydroxy-beta-methylbutyrate free acid and cold water immersion on expression of CR3 and MIP-1beta following resistance exercise. American journal of physiology Regulatory, integrative and comparative physiology. 2014; 306: R483-9. 2. Gonzalez AM, Stout JR, Jajtner AR, et al. Effects of beta-hydroxy-beta-methylbutyrate free acid and cold water immersion on post-exercise markers of muscle damage. Amino acids. 2014; 46: 1501-11. 3. Kraemer WJ, Hatfield DL, Volek JS, et al. Effects of amino acids supplement on physiological adaptations to resistance training. Medicine and science in sports and exercise. 2009; 41: 1111-21. 4. Townsend JR, Fragala MS, Jajtner AR, et al. beta-Hydroxy-beta-methylbutyrate (HMB)-free acid attenuates circulating TNF-alpha and TNFR1 expression postresistance exercise. Journal of applied physiology. 2013; 115: 1173-82. 5. van Someren KA, Edwards AJ, Howatson G. Supplementation with beta-hydroxy-beta-methylbutyrate (HMB) and alpha-ketoisocaproic acid (KIC) reduces signs and symptoms of exercise-induced muscle damage in man. International journal of sport nutrition and exercise metabolism. 2005; 15: 413-24. 6. Alway SE, Pereira SL, Edens NK, et al. beta-Hydroxy-beta-methylbutyrate (HMB) enhances the proliferation of satellite cells in fast muscles of aged rats during recovery from disuse atrophy. Experimental gerontology. 2013; 48: 973-84. 7. Wilkinson DJ, Hossain T, Hill DS, et al. Effects of leucine and its metabolite beta-hydroxy-beta-methylbutyrate on human skeletal muscle protein metabolism. The Journal of physiology. 2013; 591: 2911-23. 8. Giron MD, Vilchez JD, Shreeram S, et al. beta-Hydroxy-beta-methylbutyrate (HMB) normalizes dexamethasone-induced autophagy-lysosomal pathway in skeletal muscle. PloS one. 2015; 10: e0117520. 9. Kimura K, Cheng XW, Inoue A, et al. beta-Hydroxy-beta-methylbutyrate facilitates PI3K / Akt-dependent mammalian target of rapamycin and FoxO1 / 3a phosphorylations and alleviates tumor necrosis factor alpha / interferon gamma-induced MuRF-1 expression in C2C12 cells. Nutrition research. 2014; 34: 368-74. 10. Eley HL, Russell ST, Tisdale MJ. Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate. American journal of physiology Endocrinology and metabolism. 2008; 295: E1409-16. 11. Eley HL, Russell ST, Baxter JH, et al. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. American journal of physiology Endocrinology and metabolism. 2007; 293: E923-31. 12. Eley HL, Russell ST, Tisdale MJ. Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate. American journal of physiology Endocrinology and metabolism. 2008; 295: E1417-26. 13. Pimentel GD, Rosa JC, Lira FS, et al. beta-Hydroxy-beta-methylbutyrate (HMbeta) supplementation stimulates skeletal muscle hypertrophy in rats via the mTOR pathway. Nutrition & metabolism. 2011; 8: 11. 14. Lieberman HR, Bathalon GP, Falco CM, et al. Severe decrements in cognition function and mood induced by sleep loss, heat, dehydration, and undernutrition during simulated combat. Biological psychiatry. 2005; 57: 422-9. 15. Nindl BC, Leone CD, Tharion WJ, et al. Physical performance responses during 72 h of military operational stress. Medicine and science in sports and exercise. 2002; 34: 1814-22. 16. McClung JP, Martini S, Murphy NE, et al. Effects of a 7-day military training exercise on inflammatory biomarkers, serum hepcidin, and iron status. Nutrition journal. 2013; 12: 141. 17. Nindl BC, Scofield DE, Strohbach CA, et al. IGF-I, IGFBPs, and inflammatory cytokine responses during gender-integrated Israeli Army basic combat training. Journal of strength and conditioning research / National Strength & Conditioning Association. 2012; 26 Suppl 2: S73-81. 18. Hoffman JR, Gepner Y, Stout JR, et al. beta-Hydroxy-beta-methylbutyrate attenuates cytokine response during sustained military training. Nutrition research. 2016; 36: 553-63. 19. Kraemer WJ, Hatfield DL, Comstock BA, et al. Influence of HMB supplementation and resistance training on cytokine responses to resistance exercise. Journal of the American College of Nutrition. 2014; 33: 247-55. 20. Fuller JC, Sharp RL, Angus HF, et al. Comparison of availability and plasma clearance rates of beta-hydroxy-beta-methylbutyrate delivery in the free acid and calcium salt forms. The British journal of nutrition. 2015; 114: 1403-9. 21. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nature reviews Gastroenterology & hepatology. 2010; 7: 503-14. 22. Sanders ME. Probiotics: definition, sources, selection, and uses. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008; 46 Suppl 2: S58-61; discussion S144-51. 23. Wang Y, Gu Q. Effect of probiotic on growth performance and digestive enzyme activity of Arbor Acres broilers. Research in veterinary science. 2010; 89: 163-7. 24. Nissen S, Van Koevering M, Webb D. Analysis of beta-hydroxy-beta-methyl butyrate in plasma by gas chromatography and mass spectrometry. Analytical biochemistry. 1990; 188: 17-9. 25. Froeling M, Oudeman J, Strijkers GJ, et al. Muscle changes detected with diffusion-tensor imaging after long-distance running. Radiology. 2015; 274: 548-62. 26. Deux JF, Malzy P, Paragios N, et al. Assessment of calf muscle contraction by diffusion tensor imaging. European radiology. 2008; 18: 2303-10. 27. Damon BM, Ding Z, Anderson AW, et al. Validation of diffusion tensor MRI-based muscle fiber tracking. Magnetic resonance in medicine. 2002; 48: 97-104. 28. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC medical research methodology. 2001; 1: 6. 29. Fuller JC, Jr., Sharp RL, Angus HF, et al. Free acid gel form of beta-hydroxy-beta-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. The British journal of nutrition. 2011; 105: 367-72. 30. Bouillon R, Van Cromphaut S, Carmeliet G. Intestinal calcium absorption: Molecular vitamin D mediated mechanisms. Journal of cellular biochemistry. 2003; 88: 332-9. 31. Honda H, Gibson GR, Farmer S, et al. Use of a continuous culture fermentation system to investigate the effect of GanedenBC30 (Bacillus coagulans GBI-30, 6086) supplementation on pathogen survival in the human gut microbiota. Anaerobe. 2011; 17: 36-42. 32. Portal S, Zadik Z, Rabinowitz J, et al. The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled study. European journal of applied physiology. 2011; 111: 2261-9. 33. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exercise immunology review. 2006; 12: 6-33. 34. Welc SS, Clanton TL. The regulation of interleukin-6 implicates skeletal muscle as an integrative stress sensor and endocrine organ. Experimental physiology. 2013; 98: 359-71. 35. Febbraio MA, Steensberg A, Keller C, et al. Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans. The Journal of physiology. 2003; 549: 607-12. 36. Lundeland B, Gundersen Y, Opstad PK, et al. One week of multifactorial high-stress military ranger training affects Gram-negative signalling. Scandinavian journal of clinical and laboratory investigation. 2012; 72: 547-54. 37. Henning PC, Scofield DE, Spiering BA, et al. Recovery of endocrine and inflammatory mediators following an extended energy deficit. The Journal of clinical endocrinology and metabolism. 2014; 99: 956-64. 38. Peterson JM, Feeback KD, Baas JH, et al. Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. Journal of applied physiology. 2006; 101: 1394-9. 39. Wojdasiewicz P, Poniatowski LA, Kotela A, et al. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Archivum immunologiae et therapiae experimentalis. 2014; 62: 395-403. 40. van Zuiden M, Kavelaars A, Amarouchi K, et al. IL-1beta reactivity and the development of severe fatigue after military deployment: a longitudinal study. Journal of neuroinflammation. 2012; 9: 205. 41. Suzuki K, Nakaji S, Yamada M, et al. Systemic inflammatory response to exhaustive exercise. Cytokine kinetics. Exercise immunology review. 2002; 8: 6-48. 42. Nyangale EP, Farmer S, Cash HA, et al. Bacillus coagulans GBI-30, 6086 Modulates Faecalibacterium prausnitzii in Older Men and Women. The Journal of nutrition. 2015; 145: 1446-52. 43. Reikeras O. Immune depression in musculoskeletal trauma. Inflammation research : official journal of the European Histamine Research Society [et al]. 2010; 59: 409-14. 44. Lazarus JJ, Kay MA, McCarter AL, et al. Viable Borrelia burgdorferi enhances interleukin-10 production and suppresses activation of murine macrophages. Infection and immunity. 2008; 76: 1153-62. 45. Peake JM, Della Gatta P, Suzuki K, et al. Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. Exercise immunology review. 2015; 21: 8-25. 46. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. American journal of physiology Regulatory, integrative and comparative physiology. 2010; 298: R1173-87. 47. Paulsen G, Mikkelsen UR, Raastad T, et al. Leucocytes, cytokines and satellite cells: what role do they play in muscle damage and regeneration following eccentric exercise? Exercise immunology review. 2012; 18: 42-97. 48. Kanda K, Sugama K, Hayashida H, et al. Eccentric exercise-induced delayed-onset muscle soreness and changes in markers of muscle damage and inflammation. Exercise immunology review. 2013; 19: 72-85. 49. Cermak NM, Noseworthy MD, Bourgeois JM, et al. Diffusion tensor MRI to assess skeletal muscle disruption following eccentric exercise. Muscle & nerve. 2012; 46: 42-50.

Claims

1. 1. A composition for use in a method for improving absorption of β-hydroxy-β-methylbutyric acid (HMB) in an animal in need thereof, comprising 0.5 g to 30 g of HMB and at least one probiotic as an absorption enhancer, The composition is administered to an animal; Administration of HMB with an absorption enhancer improves the absorption of HMB compared to administration of HMB alone. The probiotic is Bacillus coagulans, Improved absorption of HMB leads to improved muscle integrity of the rectus femoris; The composition.

2. 2. The composition of claim 1, wherein the HMB is selected from the group consisting of its free acid form, its salts, its esters, and its lactones.

3. 2. The composition of claim 1, wherein the HMB is a calcium salt.

4. 2. The composition of claim 1, wherein the HMB is in the form of a free acid.

5. 1. A composition for use in a method for increasing blood levels of beta-hydroxy-beta-methylbutyric acid (HMB) in an animal in need thereof, comprising 0.5 g to 30 g of HMB and at least one probiotic as an absorption enhancer, The composition is administered to an animal; Administration of an absorption enhancer and HMB increases blood levels of HMB compared to administration of HMB alone. The probiotic is Bacillus coagulans, Increased blood levels of HMB lead to improved muscle integrity in the rectus femoris; The composition.

6. 6. The composition of claim 5, wherein the HMB is selected from the group consisting of its free acid form, its salts, its esters and its lactones.

7. 6. The composition of claim 5, wherein the HMB is a calcium salt.

8. 6. The composition of claim 5, wherein the HMB is in the form of the free acid.

9. 1. A composition for use in a method for improving absorption of β-hydroxy-β-methylbutyric acid (HMB), comprising: HMB; and at least one probiotic as an absorption enhancer, comprising: The composition is administered in an effective amount, Administration of HMB with an absorption enhancer improves the absorption of HMB compared to administration of HMB alone. The probiotic is Bacillus coagulans, Improved absorption of HMB leads to improved muscle integrity of the rectus femoris; The composition.

10. The composition of claim 9, wherein the HMB is selected from the group consisting of its free acid form, its salts, its esters and its lactones.

11. 10. The composition of claim 9, wherein the HMB is a calcium salt.

12. 10. The composition of claim 9, wherein the HMB is in the form of a free acid.

13. A composition for use in a method for increasing blood levels of HMB, comprising β-hydroxy-β-methylbutyric acid (HMB) and at least one probiotic as an absorption enhancer, comprising: The composition is administered in an effective amount, Administration of an absorption enhancer and HMB increases blood levels of HMB compared to administration of HMB alone. The probiotic is Bacillus coagulans, Increased blood levels of HMB result in improved muscle integrity of the rectus femoris; The composition.

14. The composition of claim 13, wherein the HMB is selected from the group consisting of its free acid form, its salts, its esters and its lactones.

Citation Information

Patent Citations

  • Absorption inhibitor for purine body

    JP2010132585A

  • Methods to enhance muscle regeneration in aging muscles

    JP2016520050A

  • Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)

    US20120053240A1

  • Method of enhancing immune response of mammals

    US4992470A

  • Method of raising meat producing animals to increase lean tissue development

    US5028440A